Read More Pharma Industry News Horizon Therapeutics’ Daxdilimab Phase 2 trial fails to reach primary endpoint in SLE Horizon Therapeutics plc (Nasdaq: HZNP) announced that its Phase 2 clinical trial studying the efficacy of daxdilimab in… byPallavi MadhirajuJuly 22, 2023